Research Topics
| Carlo TortiSummaryCountry: Italy Publications
| Collaborators
|
Detail Information
Publications
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitorsCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
J Clin Virol 35:414-9. 2006..To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in patients failing HAART with limited antiretroviral exposure...
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretroviralsCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Curr HIV Res 6:43-8. 2008..Further studies are needed to compare pVL decay between antiretroviral regimens and assess whether proviral HIV-DNA load is a surrogate marker of treatment effectiveness...
Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infectionCarlo Torti
Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Antivir Ther 9:139-42. 2004
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patientsCarlo Torti
School of Medicine, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Drug Saf 30:1161-9. 2007..Moreover, the predictive value of gender and CD4+ T-cell count on the risk of raised transaminase levels has been poorly investigated in populations of patients co-infected with hepatitis C virus (HCV)...
Predictors of AIDS-defining events among advanced naïve patients after HAARTCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, Italy
HIV Clin Trials 8:112-20. 2007..Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously...
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroCarlo Torti
Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
J Med Virol 74:29-33. 2004....
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART)Carlo Torti
Institute of Infectious and Tropical Diseases, University of Brescia, Italy
Viral Immunol 17:279-86. 2004....
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006)G Carosi
Clinica di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, P le Spedali Civili, 1, 25123, Brescia, Italy
Infection 35:134-42. 2007..A rational switch strategy should consider both metabolic and anthropometric disturbances and effectiveness of antiretroviral regimens...
Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patientsC Torti
Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
AIDS Patient Care STDS 18:629-34. 2004..In conclusion, pharmacokinetic variability and low LPV concentrations have been found, supporting the use of therapeutic drug monitoring in those starting this drug...
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case reportGiuseppe Lapadula
Institute of Infectious and Tropical Diseases, University of Brescia, Italy
J Med Case Reports 1:19. 2007..Liver biopsy may provide further important information regarding patients with severe transaminase elevation, for a better understanding of the etiology of liver damage...
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral loadCarlo Torti
Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
J Antimicrob Chemother 59:1141-7. 2007..We investigated whether tenofovir plus didanosine at a weight-adjusted dosage could be responsible for such an effect, and factors associated with CD4 + T cell count evolution under this combination...
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER CohortCarlo Torti
Istituto di Malattie Infettive e Tropicali, Universita di Brescia, Brescia, Italy
J Acquir Immune Defic Syndr 41:180-5. 2006..The independent role of hepatitis C virus (HCV) genotype 3 in liver transaminase elevation following highly active antiretroviral regimens is still controversial...
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted RegiCarlo Torti
Institute for Infectious and Tropical Diseases, Brescia, Italy
Clin Infect Dis 40:1828-36. 2005....
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER CohortCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, Italy
J Antimicrob Chemother 56:190-5. 2005....
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortCarlo Torti
Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
BMC Infect Dis 5:58. 2005....
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patientsCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
Int J Antimicrob Agents 29:185-90. 2007..The presence of HCV and/or HBV co-infections correlated with higher plasma drug concentrations, although it did not appear to influence hepatotoxicity risk...
Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retroviralsC Torti
Institute of Infectious and Tropical Diseases, University of Brescia, 25123 Brescia, Italy
Clin Microbiol Infect 10:826-30. 2004..These findings support the use of resistance testing in patients naïve for anti-retroviral therapy, and suggest that the possible impact of newly recognised treatment-related mutations on clinical outcome requires further investigation...
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implicationsC Torti
Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy
Epidemiol Infect 138:1298-307. 2010..The evidence of inter-subtype recombinants points to significant genetic assortment. Overall our results support phylogenetic analysis as a tool for epidemiological investigation in order to guide targeted prevention strategies...
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER CohortsC Torti
School of Medicine, Institute of Infectious and Tropical Diseases, University of Brescia, P le Spedali Civili, 1, 25123, Brescia, Italy
Infection 37:244-9. 2009....
Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapyCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Antivir Ther 10:505-13. 2005....
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitorsGiuseppe Lapadula
Clinic for Infectious Diseases and Tropical Medicine, University of Brescia, Brescia, Italy
Antivir Ther 13:601-5. 2008..Prevalence and factors associated with etravirine (EW) resistance mutations among patients failing on first-generation non-nucleoside reverse transcriptase inhibitors (NNRTI) merit investigation...
Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infectionMonia Mendeni
Institute of Infectious and Tropical Diseases, University of Brescia, Italy
Clin Infect Dis 52:1164-73. 2011..There is lack of data on the incidence of liver fibrosis (LF) progression in patients with human immunodeficiency virus (HIV) monoinfection and risk factors for LF...
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIVEugenia Quiros-Roldan
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Antivir Ther 13:341-8. 2008..The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations...
Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcomeMassimo Puoti
Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, Italy
J Acquir Immune Defic Syndr 32:259-67. 2003..To assess incidence, risk factors, histology, and outcome of severe hepatotoxicity (SH) during antiretroviral treatment (ART)...
Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysisGiuseppe Lapadula
Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
J Med Virol 80:747-53. 2008..38; 95% CI:0.17-0.86; P = 0.020). Prevalence of primary resistance mutations suggests that genotypic resistance testing should be performed before starting treatment in naïve patients in Italy, particularly when NNRTI are prescribed...
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3Giuseppe Lapadula
Institute for Infectious and Tropical Diseases, University of Brescia, Italy
Antivir Ther 12:941-7. 2007..Baseline and follow-up predictors of new AIDS-defining events (ADE) or death among patients who started HAART with CD4+ T-cell counts > or =200 cells/mm3 have rarely been assessed simultaneously...
Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical caseCarlo Torti
Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Med Sci Monit 9:CS16-9. 2003..Resistance testing on the proviral genome has been suggested in order to detect the presence of archived resistance mutations and to guide drug prescription...
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapyGiuseppe Lapadula
Istituto per le Malattie Infettive e Tropicali, , Brescia, Italy
Antivir Ther 11:521-7. 2006..This effect was particularly attributed to HCV-3, which was the only genotype associated with lower triglyceridaemia during HAART...
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapyEugenia Quiros Roldan
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
AIDS Patient Care STDS 21:92-9. 2007..4; 95% CI 0.2-0.8; p = 0.014) were both negative independent predictors of sustained virologic response, while the use of boosted protease inhibitor-containing regimens resulted to be protective (OR: 2.4; 95% CI 1.1-5.3; p = 0.032)...
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapyEugenia Quiros-Roldan
Infectious Diseases Clinic, University of Brescia, Italy
J Clin Lab Anal 16:76-8. 2002..A slow decline in the detectability of mutations encoding NNRTI resistance was found...
Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal studyAndrea Patroni
Institute of Infectious and Tropical Diseases, University of Brescia, Italy
HIV Clin Trials 3:451-61. 2002..Lipid disturbances have also been associated with hepatitis C virus (HCV) chronic infection in HIV-uninfected participants. HAART-induced lipid abnormalities may then have peculiar features in HIV-HCV co-infected individuals...
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAARTMaria Cristina Uccelli
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Ann Nutr Metab 50:247-52. 2006..Homocysteinemia (Hcy) increase and risk factors in HIV-positive patients are not clear yet...
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patientsCarlo Torti
Institute of Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
J Infect Dis 188:194-201. 2003..52-5.52; P=.001; RetroGram: OR, 2.34; 95% CI, 1.21-4.55; P=.012), whereas, in contrast to real or virtual phenotype, interpretations according to biological cut-offs were not (OR, 1.91; 95% CI, 0.77-4.76; P=.162)...
Screening and Management of HIV-2-Infected Individuals in Northern ItalySilvia Costarelli
Institute of Infectious and Tropical Diseases, University of Brescia, Brecia, Italy
AIDS Patient Care STDS 22:489-94. 2008..Accurate screening programs and integration of virological tools must be implemented urgently, given the high prevalence of HIV-2, particularly in immigrant patients...
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapyAntonella Castagna
Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
Antivir Ther 15:165-75. 2010..The extent of short-term CD4(+) T-cell recovery in patients tolerating first-line highly active antiretroviral therapy (HAART) and attaining undetectable HIV RNA levels is inadequately defined...
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenzLaura Albini
Department of Materno Infantile e Tecnologie Biomediche, Institute of Infectious and Tropical Diseases, University of Brescia, Italy
J Acquir Immune Defic Syndr 59:18-30. 2012..There is lack of data on GFR estimated by these methods in patients on highly active antiretroviral therapy...
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target?Eugenia Quiros-Roldan
Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Intervirology 47:350-4. 2004....
SENV infection in HIV-positive patients: prevalence, subtype characterization, and impact on HIV disease progressionEugenia Quiros-Roldan
Department of Infectious and Tropical Diseases, Spedali Civili of Brescia, 25123, Italy
AIDS Res Hum Retroviruses 19:1079-82. 2003..At multivariate analysis, SENV infection did not appear to have any negative impact on survival, while a possible protective effect needs further investigation...
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus WorkshopGiampiero Carosi
Department of Infectious Disease, University of Brescia, Brescia, Italy
AIDS Rev 7:161-7. 2005....
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based settingCarlo Torti
Institute of Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
Health Policy 65:261-7. 2003..To assess the impact of highly active antiretroviral therapy (HAART) on health resource utilisation (HRU) and to estimate associated direct costs in a population based setting...
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenzEmanuele Focà
Infectious Diseases Department, University of Brescia, Brescia, Italy
BMC Infect Dis 12:38. 2012..Lastly, the effect of tenofovir on 1,25-(OH)₂ vitamin D is uncertain...
Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for useEmanuele Focà
Department for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Drugs 72:1161-73. 2012..Moreover, therapeutic drug monitoring could be useful in specific circumstances (such as in patients with liver impairment or in case of potential drug-drug interactions)...
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTICarlo Torti
University of Brescia, Italy
BMC Infect Dis 11:23. 2011..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce...
Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapyEmanuele Focà
Infectious Diseases Department, University of Brescia, Brescia, Italy
New Microbiol 35:227-31. 2012..At the same time, HAART proved effective in reducing HCMV DNAemia without the need for a specific therapy...
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy)Ilaria Izzo
Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy
BMC Public Health 11:124. 2011..Therefore, we examined pregnant women by regional provenance and measured variables that could be associated with detectable HIV RNA at delivery...
A king in the CASTLE? Optimum initial HIV protease inhibitorCarlo Torti
Institute of Infectious and Tropical Diseases, University of Brescia, I 25123 Brescia, Italy
Lancet 372:604-6. 2008
Natural history of chronic hepatitis B in co-infected patientsMassimo Puoti
Clinica di Malattie Infettive e Tropicali, AO Spedali Civili, Universita di Brescia, P zzle Spedali Civili 1, I 25123 Brescia, Italy
J Hepatol 44:S65-70. 2006....
Characterization of viro-immunological responses in a closely followed cohort of heavily pretreated patients: evidence from the GenPheRex StudyC Torti
Institute of Infectious and Tropical Diseases, University of Brescia, Italy
HIV Med 4:263-70. 2003..To assess prevalence and predictive factors of viro-immunological discordant trends in a cohort of heavily pretreated patients...
High prevalence of radiological vertebral fractures in HIV-infected malesCarlo Torti
Institute of Infectious and Tropical Diseases, School of Medicine, University of Brescia, P le Spedali Civili, 1, 25123 Brescia, Italy
Endocrine 41:512-7. 2012..Furthermore, proactive diagnosis of vertebral fragility fractures is particularly relevant in patients who are overweight or suffer from diabetes...
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class receivedDavide Motta
Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
AIDS Res Ther 9:18. 2012..abstract:..
[New strategies and new drugs in the salvage therapy for HIV infection]Eugenia Quiros-Roldan
Institute of Infectious and Tropical Diseases, University of Brescia, Italy
Med Clin (Barc) 118:222-4. 2002
Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switchL R Tomasoni
Institute for Infectious and Tropical Diseases, University of Brescia, Italy
HIV Clin Trials 4:311-23. 2003....
HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatmentE Quiros-Roldan
Clinica de Malattie Infettive e Tropicali, , Italy
Microbios 106:137-45. 2001..85%) than in other studies, which ranged from 2 to 19%. The M184V mut seemed to confer some viro-immunological benefit when associated with the Q151M mutation, compared with the latter alone...
"Solving the puzzle" of current HAART: what key strategic trials are needed?G Carosi
Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Brescia, Italy
New Microbiol 27:127-30. 2004..As a consequence, new more effective and tolerable antiretroviral agents and regimens are needed, as well as new strategies for HIVdisease management. Strategically driven clinical researches are needed to address these issues...
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patientsEugenia Quiros-Roldan
Laboratory of Biotechnology, Diagnostics Department, Spedali Civili of Brescia, Brescia, Italy
J Transl Med 10:94. 2012..abstract:..
[The novel non-A, non-E hepatitis viruses and their pathogenic effect]Eugenia Quiros-Roldan
Institute of Infectious and Tropical Diseases, Spedali Civili, Brescia, Italy
Med Clin (Barc) 122:552-4. 2004..Only a careful evaluation of the data and the scientific concordance of all the evidence will resolve the question of whether they are only commensal viruses or pose a real pathogenic potential...
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimensE Quiros-Roldan
Institute of Infectious and Tropical Diseases, Spedali Civili of Brescia, University of Brescia, Brescia, Italy
J Clin Lab Anal 19:26-9. 2005..The use of NFV as a first-line PI, as an application of drug sequencing strategies, may help preserve future PI options...
Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infectionE Quiros-Roldan
Institute for Infectious and Tropical Diseases, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
Eur J Clin Microbiol Infect Dis 24:436-7. 2005
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapyE Quiros-Roldan
Institute of Infectious and Tropical Diseases, University of Brescia, Italy
J Clin Lab Anal 15:43-6. 2001..Twelve of our patients (12.9%) had no mutation encoding drug resistance and were completely sensitive to all RT and protease inhibitors. Therefore, not all virological failures are caused by HIV-1 genomic resistance...
Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of HerculesDaria Gotti
Institute for Infectious and Tropical Disease, University of Brescia, Brescia, Italy
Curr HIV Res 9:61-9. 2011....
Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction?Carlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, P le Spedali Civili, 125123 Brescia, Italy
BMC Med 9:138. 2011..Moreover, it is important to understand whether new biomarkers or neuroimaging tools can help to identify better the most at risk population. Please see related article: http://www.biomedcentral.com/1471-2334/11/356...
Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillanceManuela Fogli
Section of Microbiology, Department of Experimental and Applied Medicine, University of Brescia, Spedali Civili Square, 25123 Brescia, Italy
Clin Dev Immunol 2012:829584. 2012..These results provide new insights on B cell in HIV-1 infection and show that development of B cell abnormalities precedes CD4⁺ T cell decline...
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignanciesAntonella D arminio Monforte
Dipartimento di Medicina, Chirurgia e Odontoiatria, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera Polo Universitario San Paolo, via A Di Rudinì 8 20142 Milano, Italy
AIDS 22:2143-53. 2008..To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency...
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005)G Carosi
Department of Infective and Tropical Diseases, University of Brescia, Piazzale Spedali Civili I, I 25123 Brescia, Italy
J Antimicrob Chemother 57:1055-64. 2006..Main conclusions are summarized and critically discussed in this consensus statement, as well as some of the most recent data supporting these recommendations are provided...
Soil transmitted helminth (STH) infections in an indigenous community in Ortigueira, Paraná, Brazil and relationship with its nutritional statusA Beltrame
Department of Infectious and Tropical Diseases, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
Parassitologia 44:137-9. 2002..These results strongly suggested that mass treatment would be indicated in the indigenous community, possibly leading to improved nutritional status...
Bcl-2 expression is moderately correlated with long-term variability of CD4 T-cell increase under successful highly active antiretroviral therapyMaria Cristina Uccelli
AIDS 17:141-3. 2003
Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of reboundLina Tomasoni
J Infect Dis 186:445-6. 2002
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapyCarlo Torti
J Acquir Immune Defic Syndr 29:315-7. 2002
[Usefulness of pharmacokinetics in the management of antiretroviral therapy]Eugenia Quiros-Roldan
Med Clin (Barc) 124:695-6. 2005
Response to combination antiretroviral therapy: variation by ageIan Weller
AIDS 22:1463-73. 2008..The poorer virological responses in children may increase the likelihood of emergence of resistance...
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutationAndrea Antinori
National Institute for Infectious Diseases L Spallanzani IRCCS, Roma, Italy
Antivir Ther 12:1175-83. 2007..The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined...
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAARTAnnalisa Saracino
Clinic of Infectious Diseases, University of Foggia, Foggia, Italy
J Med Virol 80:1695-706. 2008..Therefore, in some cases DNA plus RNA genotyping might assist in choosing more accurately subsequent antiretroviral regimens...
Genotyping for guiding drug choice in human immunodeficiency virus-infected children failing multiple antiretroviral treatment regimensRaffaele Badolato
Pediatr Infect Dis J 24:747-9. 2005
The development of artificial neural networks to predict virological response to combination HIV therapyBrendan Larder
The HIV Resistance Response Database Initiative, London, UK
Antivir Ther 12:15-24. 2007..The choice of an alternative regimen may be guided by a drug-resistance test. However, interpretation of resistance from genotypic data poses a major challenge...
Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen)Annalisa Saracino
Clinic of Infectious Diseases, University of Foggia, Foggia, Italy
J Acquir Immune Defic Syndr 37:1587-98. 2004..55; P = 0.001), and adherence to expert advice (OR = 0.37; P < 0.001) predicted virologic response. The vPt is as predictive of treatment outcome as the rPT. Use of expert advice significantly improved the response to therapy...
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlationsCarlo Torti
J Acquir Immune Defic Syndr 36:1104-7. 2004
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patientsSilvia Costarelli
J Acquir Immune Defic Syndr 46:255-6. 2007
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrationsCarlo Torti
J Acquir Immune Defic Syndr 35:324-6. 2004
Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage studyNicola Gianotti
Clinica di Malattie Infettive, Universita Vita Salute San Raffaele, Milan, Italy
Clin Infect Dis 42:1470-80. 2006..There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results...
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patientsGiuseppe Lapadula
Clin Infect Dis 46:1127-9. 2008
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretationsLuigia Scudeller
Institute of Infectious Diseases, University of Udine, Udine
J Antimicrob Chemother 52:776-81. 2003..However, our results indicate that a number of mutations may have an impact on APV resistance, but that they are missed by current interpretation algorithms and this merits further investigations...
The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimensFranco Maggiolo
Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy
Antivir Ther 11:923-9. 2006..One of the more vigorous debates in the field of highly active antiretroviral therapy (HAART) is how to start it and what the optimal drug sequence is...
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trialFrancesco Mazzotta
Department of Infectious Diseases, S.M. Annunziata Hospital, ASL Firenze, Italy
J Acquir Immune Defic Syndr 32:268-80. 2003..Several factors should be considered to take better advantage of resistance testing, including treatment history, clinical status, and patients' ability to adhere to treatment...
No evidence of benefical effect of GB virus type C infection on the course of HIV infectionEugenia Quiros-Roldan
AIDS 16:1430-1. 2002
Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of responseGiulio Perugi
Institute of Behavioral Sciences G De Lisio, Carrara, Italy
Neuropsychobiology 46:145-9. 2002..Our data confirm the effectiveness and tolerability of SR-VF in mixed anxiety-depressive states. The differential response suggests a pathophysiologic and clinical distinction between GAD with comorbid MD or dysthymia...
Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?Giulio Perugi
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, Psychiatry Section, University of Pisa, Pisa, Italy
J Clin Psychopharmacol 22:584-91. 2002..What is new in the present report is the suggestion that the utility of GBP in resistant bipolar disorder resides in its effectiveness against comorbid panic disorder and alcohol abuse...
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesisAndrea Gori
Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano Bicocca, Via Solferino 16 20052, Milan, Italy
J Clin Microbiol 46:757-8. 2008..This impairment is associated with alterations in gut microbiota and intestinal inflammatory parameters. These findings support the hypothesis that alterations at the gastrointestinal-tract level are a key factor in HIV pathogenesis...
